Articles tagged with Colon Cancer
CDX2 is an identity gene that tells a cell it is in the epithelial tissue of the intestine, enabling it to perform its job correctly. Cancer cells deactivate this gene, leading researchers to identify five anti-cancer genes and discover CDX2's role in suppressing colon cancer.
A new analysis found that rectal cancer rates are rising among young people under 40, with a 3.8% annual increase between 1984 and 2005. The study suggests that endoscopic evaluation should be considered for individuals presenting with rectal bleeding or other signs of the disease.
Researchers at Tel Aviv University discovered that low hemoglobin levels can indicate a potential for colon cancer years before it's diagnosed. A continuous long-term decline of more than 0.28 grams per decilitre over a four-year period may serve as a warning of illness on the horizon.
A study published in The Journal of the National Cancer Institute found that computed tomographic colonography (CTC) screening every five years is not cost-effective if reimbursed at the same rate as colonoscopy. However, CTC would be cost-effective if it enticed 25% more individuals to screen.
A UNC physician authored an editorial on a cost-effectiveness study comparing colonoscopy and computed tomographic colonography (CTC) for colon cancer screening. The analysis concluded that CTC is not cost-effective compared to colonoscopy if reimbursed at the same rate.
Researchers at Tel Aviv University are developing a new clinical approach to prevent cancer recurrence after surgery by blocking stress responses. The treatment involves combining two widely available medications to boost the immune system and prevent tumor metastasis, with promising results in animal studies.
Researchers have developed a new technique combining flexible sigmoidoscopy with optical technologies to detect colon cancer more accurately in women. The test identified subtle changes in tissue that indicate the presence of cancer, providing hope for improving discrepancies in screening accuracy between men and women.
A study found that smoking is associated with molecularly defined DNA changes and a subtype of colorectal cancer that emerges more frequently among older women. The researchers suggest that epigenetic modifications may play a role in the development of smoking-related colorectal carcinogenesis.
A Kaiser Permanente Center for Health Research study found that simple, automated telephone reminders can increase colon cancer screening rates by 30 percent. The study, which involved nearly 6,000 members in Oregon and Washington, showed that people were more likely to get screened after receiving automated reminders.
Researchers at UNC Chapel Hill discovered a link between altered gut microbiota and colon cancer, finding higher bacterial diversity and richness in individuals with adenomas. The study suggests that manipulating the microbiota through diet could help prevent colon cancer.
Researchers found APC plays a crucial role in renovating the actin cytoskeleton by triggering actin assembly, offering a second way mutations in APC could lead to cancer. The study suggests APC's impact on the cytoskeleton may contribute to cancer development, especially when its actin-binding section is mutated.
Patients with stage II colon cancer treated after 1995 had longer time to recurrence, but improved overall survival. Stage III colon cancer patients treated after 1995 also showed improved overall survival without change in time to recurrence compared to those treated before 1995.
Researchers found that specific bacterial signatures were associated with polyps, early lesions that can develop into colon cancer. The study suggests the development of non-invasive screening tests and diet-based prevention regimens to reduce CRC risk.
A large study found no association between coffee, tea, or sugar-sweetened soft drinks and colon cancer risk. High tea consumption was linked to a modest increase in risk, but the connection is unclear.
A meta-analysis found that the G allele of PPAR-γ gene polymorphism 34 C>G decreases colon cancer risk, indicating its potential as an early diagnosis and treatment target. The study confirms previous data linking the polymorphism to CRC risk.
Researchers at Henry Ford Hospital discovered a pill that halves the required liquid intake for colonoscopy prep, improving bowel preparation quality and patient tolerance. The pill, lubiprostone, was added to an electrolyte mix, reducing volume requirements.
A recent study published by Mayo Clinic has found that older women with diabetes are at a more than doubled risk for certain types of colorectal cancer. The research team analyzed data from over 37,000 participants and identified associations between diabetes and specific molecular markers.
Research suggests that epigenetics plays a key role in the development of degenerative diseases. Environmental influences can alter gene expression, which can be passed on to offspring and impact life and death. HDAC inhibitors, found in foods like broccoli and garlic, may help prevent cancer by silencing tumor suppressor genes.
Researchers from Oregon State University are exploring the link between epigenetics, diet, and disease prevention. They found that HDAC inhibitors, found in foods like broccoli and garlic, can stop degenerative processes and turn off tumor suppressor genes.
A new study has found that genetically short-circuiting the ability of cancer stem cells to absorb a key nutrient can kill many colon cancer cells. The approach targets tumor cell 'factories' and could potentially reduce recurrence rates of colon cancer. However, further research is needed to ensure the treatment does not harm normal s...
Scientists developed a urine test for detecting colon cancer by analyzing chemical differences in human urine samples. The study identified 16 substances associated with colon cancer, offering potential for an alternative screening method to colonoscopy.
Researchers at Fox Chase Cancer Center have found that a new form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block early molecular changes leading to colorectal cancer development while reducing gastrointestinal toxicity. This novel agent may be more effective than standard naproxen in inhibiting tumor growth.
A blood test measuring C-reactive protein (CRP) levels may help assess colon cancer risk, according to a Vanderbilt University Medical Center study. High CRP levels were found to be associated with a 2.5-times greater risk of colon cancer in women.
Researchers discovered that specific inflammasome components protect against colitis and cancer in mice. Mice lacking these components developed more severe colitis and larger tumor burdens, highlighting the complex role of inflammasomes in human disease.
A research group at Case Western Reserve University found that Recql5 mutation had an important impact on tumorigenesis in the mouse GI tract. The study also suggested that Recql5 may be an important candidate for a colon cancer biomarker, and its expression was recently shown to affect sensitivity to camptothecin-based anticancer drugs.
A combination of Vitamin A acetate and TRAIL kills precancerous colon polyps while sparing normal tissue, providing a potential new avenue for chemoprevention. The regimen, tested in mouse models and human colon cancer tissue, appears to address the issue of continuous long-term therapy required for current chemopreventive drugs.
Researchers developed a vaccine targeting an abnormal protein MUC1, found in both IBD and colon cancer. The vaccine delayed IBD development and reduced inflammation, reducing cancer risk.
A large-scale study of 10,000 adults found that virtual colonoscopy identifies more unsuspected cancers outside the colon than within it. The majority of these cancers were detected at an early stage and have positively affected survival.
A new study found that older patients with stage III colon cancer are less likely to receive chemotherapy after surgery due to concerns about adverse events. However, the study discovered that when they do receive chemotherapy, it is less toxic and of shorter duration compared to younger patients, resulting in fewer adverse events.
A RAND-UCLA study found that patients with stage III colon cancer receive chemotherapy at a lower rate than recommended, with older patients being less likely to receive the strongest treatment. Despite this, older patients do not experience more adverse outcomes compared to younger patients.
A study found that new chemotherapy agents for metastatic colorectal cancer improve life expectancy by 6.8 months and increase lifetime medical costs by $37,100, equating to a cost of $66,200 per year of life gained.
A study published in Clinical Cancer Research found that obesity is a significant risk factor for poorer overall survival and death in patients with stage II or III colon cancer. Men with higher body mass indexes had a 35% increased risk of death compared to normal-weight patients.
Researchers identified two biomarkers in the blood that may accurately predict the spread of colon cancer, allowing for earlier intervention and treatment. The study found these biomarkers were significantly higher in metastatic cells than primary tumor cells.
Researchers identify a gene signature that predicts colon cancer recurrence and death, allowing for personalized chemotherapy targeting and avoiding toxic treatments.
Researchers found that toxin Paton-Valentine leukocidin does not affect MRSA-induced pneumonia. A novel inhibitor of tumor angiogenesis was discovered in the metalloprotease ADAMTS9. Additionally, Kallikrein-related peptidase 4 (KLK4) may activate protease-activated receptors promoting colon cancer development.
Researchers at the University of Texas Health Science Center at Houston are working on cutting-edge projects to protect girls from cervical cancer and develop new approaches for treating colon cancer. The center has received over half of the $61M awarded by CPRIT, with grants totaling $4.5M.
Researchers at George Mason University are conducting a clinical trial to treat late-stage colorectal cancer patients with tailored therapies based on their tumor's protein profile. The trial uses a novel drug target mapping technology and Gleevec, a medicine typically prescribed for leukemia and gastrointestinal tumors.
The study found that mortality due to colon cancer increased between 1951 and 2000, but stabilized in men and decreased in women between 2000 and 2006. The main causes of these disparities include tobacco consumption and red meat intake.
Researchers at Texas A&M AgriLife Communications discovered that mango polyphenols can prevent or stop growth of certain breast and colon cancer cells. The study found that the fruit's antioxidants had a significant impact on these specific types of cancer, with some cell lines undergoing programmed cell death.
A combined PET-CT scan can accurately detect cancer in patients with neurologic symptoms more effectively than other tests. The study found that PET-CT detected abnormalities suggestive of cancer in 39% of patients, leading to early treatment and improved outcomes for 12 patients.
A new study found that MSH6 mutation carriers have a high risk of developing colorectal and endometrial cancers, as well as cancers associated with Lynch syndrome. The estimated cumulative risks to ages 70 and 80 years were 22% and 44% for colorectal cancer in men, and 26% and 44% for women.
A group of heart drugs, cardiac glycosides, have been found to be effective against human colon cancer cells, with varying degrees of sensitivity. The findings suggest that these heart drugs could potentially improve colon cancer outcomes when used alone or in combination with conventional chemotherapy.
Key advances in DNA sequencing technology and gene mutations have identified candidate cancer genes that contribute to colorectal cancer. The study also highlights the importance of understanding biological pathways deregulated in colon cancer, which can form the basis of new therapeutic agents.
Men with a history of nonmetastatic colon cancer who engage in moderate to vigorous physical activity have a significantly lower risk of death from colon cancer and any cause. The study found that men who exercised for more than 27 MET hours per week had over 50% lower mortality rates compared to inactive men.
Researchers at the University of Florida have found a way to use reduced dosages of the chemotherapy drug TMZ to achieve better results against colon cancer cells. By combining TMZ with a small molecule, they were able to disable the ability of tumor cells to repair DNA damage.
Children's Hospital Oakland scientists discover a new class of therapeutic agents, Sphingadienes, found naturally in soy that can prevent and possibly treat colon cancer. Elevated SDs induce the death of mutant cells, revealing SDs as cytotoxic compounds.
African-Americans have lower survival rates than whites after surgery for colon cancer; the study suggests genetic variation, tumor characteristics, access to healthcare, and other factors may be involved. Obesity was found to be protective in patients with advanced-stage disease, contradicting earlier assumptions.
Researchers at Karolinska Institutet have identified a paradoxical protein that stimulates stem cell division but prevents cancer growth. The study suggests a potential new treatment using the drug imatinib to prevent colon cancer in high-risk patients.
Research finds that coffee's trigonelline compound may be beneficial in preventing colon cancer development but potentially linked to breast cancer. The compound can act like a hormone, but its impact on human health is still unclear due to complex interactions with other compounds in coffee.
A Henry Ford Hospital study suggests that patients with diverticulosis may not require aggressive screening for colonic polyps, as they tend to have fewer and less advanced polyps. The study analyzed data from 1,668 patients and found a lower incidence of polyps in those with diverticulosis.
A Tel Aviv University drug based on an older generation antibiotic shows promise in treating colon cancer by suppressing polyp growth and repairing genes. Preclinical studies have shown a 80% reduction in polyp size and a 30% increase in mouse lifespan.
Researchers at the University of Florida have found that inflammation in the colon tissue can trigger the transition from a non-cancerous state to cancer. The study suggests that targeting specific immune system hormones may be a key to preventing or inhibiting cancer growth, with potential implications for diagnostic tests and therapy.
A study published in Stem Cells reveals human stem cells can immunize against colon cancer by tricking the immune system. The discovery builds upon a century-old theory and opens up new possibilities for cancer vaccine research.
Researchers at Case Western Reserve University School of Medicine are investigating the role of genetic susceptibility in colon cancer metastasis. By identifying specific genes and variants, they aim to develop new anti-cancer therapies and improve patient outcomes.
Scientists have discovered a way to block the growth of human colon cancer cells by targeting the Hedgehog-GLI pathway, preventing tumor growth and metastasis. This breakthrough could provide a new method for treating incurable forms of colon cancer.
Researchers found that strains of Bacteroides fragilis dupe immune cells into allowing runaway colon tissue inflammation, a precursor to malignant growth. High levels of pStat3 and Th17 activity in infected mice were linked to chronic inflammation and tumor development.
A new study from the University of Michigan Comprehensive Cancer Center found that hospitals treating more black cancer patients have lower survival rates for breast and colon cancer, regardless of race. The researchers suggest that factors such as hospital resources and quality of care are key contributors to these disparities.
Scientists at the University of North Carolina have found that drugs targeting ERBB3 could be more effective in killing colon cancers resistant to current EGFR inhibitors. Genetic studies show that blocking ERBB3 can significantly reduce cell growth and induce cell death in human colon cancer cells.
Scientists have developed a highly sensitive method to detect DNA methylation in colon cancer using Methyl-BEAMing technology. The test can identify 59% of colon cancers in blood samples, a significant improvement over existing methods.
A Montreal study links heavy consumption of beer and spirits to an increased risk of six different cancers, including oesophageal, colon, lung, pancreatic, liver, and prostate cancer. Heavy drinkers face a sevenfold increased risk of esophageal cancer and an 80% higher risk of colon cancer.